YB-1113

· Bright Cell, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YB-1113, covering 2025-12-23 to 2025-12-23. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of YB-1113 in Treatment of POI [Phase 1]